Welcome
Ironwood Cancer & Research Centers strive to be comprehensive care facilities providing a full spectrum of services to patients with oncologic and hematologic diseases. Our state of the art facilities are the first of their kind in the East Valley, housing a full staff to provide leading edge, quality care in Medical Oncology along with Radiation Oncology and ancillary support services.
Latest Cancer News
Combined Modality Therapy Preserves Bladder and Offers Long-term Survival in Invasive Bladder Cancer
(03-18-2010)
Combined modality therapy (CMT) preserves the bladder, achieves complete response (CR), and offers long-term survival in approximately 70% of patients with invasive bladder cancer, according to the results... Continue Reading
Vaginal Brachytherapy Effective for Endometrial Cancer (03-17-2010)
Among women who have undergone surgery for high-intermediate risk endometrial cancer, vaginal brachytherapy is as effective as pelvic external beam radiotherapy in the prevention of vaginal recurrence... Continue Reading
Neratinib Active in Women with Advanced HER2-positive Breast Cancer (03-16-2010)
Among women with advanced HER2-positive breast cancer, the investigational drug neratinib produced promising response rates and progression-free survival. The results of this Phase II clinical trial... Continue Reading
Combined modality therapy (CMT) preserves the bladder, achieves complete response (CR), and offers long-term survival in approximately 70% of patients with invasive bladder cancer, according to the results... Continue Reading
Vaginal Brachytherapy Effective for Endometrial Cancer (03-17-2010)
Among women who have undergone surgery for high-intermediate risk endometrial cancer, vaginal brachytherapy is as effective as pelvic external beam radiotherapy in the prevention of vaginal recurrence... Continue Reading
Neratinib Active in Women with Advanced HER2-positive Breast Cancer (03-16-2010)
Among women with advanced HER2-positive breast cancer, the investigational drug neratinib produced promising response rates and progression-free survival. The results of this Phase II clinical trial... Continue Reading